查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878894

抗病毒藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物類別、配銷通路、應用、地區和競爭格局分類，2020-2030年預測

Anti-Viral Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Class, By Distribution Channel, By Application By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球抗病毒藥物市場規模為771億美元，預計2030年將以3.89%的複合年成長率成長至969.4億美元。抗病毒藥物是用來抑制病毒在宿主體內複製和增殖的藥物，進而治療或預防愛滋病、肝炎和流感等病毒感染。該市場的成長主要受全球病毒性疾病發生率上升、藥物研發投入巨資以及積極進行的公共衛生感染控制活動等因素所驅動。

市場概覽
預測期 2026-2030
2024年市場規模 771億美元
2030年市場規模 969.4億美元
2025-2030年複合年成長率 3.89%
成長最快的細分市場 品牌
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球抗病毒藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（品牌藥、學名藥）
    • 依藥物類別（DNA聚合酶抑制劑、逆轉錄酶抑制劑、蛋白酶抑制劑、神經氨酸酶抑制劑、其他）
    • 按應用（愛滋病、肝炎、皰疹、流感、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球抗病毒藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • F. Hoffmann-La Roche Ltd
  • GSK plc.
  • AbbVie, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Aurobindo Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 7550

The Global Anti-Viral Drugs Market, valued at USD 77.10 Billion in 2024, is projected to experience a CAGR of 3.89% to reach USD 96.94 Billion by 2030. Antiviral drugs are pharmaceutical agents developed to inhibit viral replication and proliferation within a host, thereby treating or preventing viral infections such as HIV, hepatitis, and influenza. The market's growth is primarily driven by the escalating global incidence of viral diseases, substantial investments in pharmaceutical research and development, and proactive public health campaigns for infection control.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 77.10 Billion
Market Size 2030USD 96.94 Billion
CAGR 2025-20303.89%
Fastest Growing SegmentBranded
Largest MarketNorth America

Key Market Drivers

The increasing global prevalence of viral infections stands as a significant driver for the antiviral drugs market, creating an enduring demand for effective therapeutic solutions. The continuous emergence of new viral strains and the persistent burden of established pathogens pose substantial public health challenges, from seasonal outbreaks to widespread epidemics. For example, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) in its 2023 Global AIDS Update, an estimated 1.3 million people worldwide became newly infected with HIV in 2022. This ongoing incidence necessitates the development of advanced antiviral treatments to manage and prevent disease progression, thereby directly influencing market demand for these crucial pharmaceutical products.

Key Market Challenges

The rapid evolution of viral resistance to existing therapeutic agents presents a significant obstacle to the sustained growth of the global anti-viral drugs market. As viruses mutate and develop resistance, the efficacy of current treatments diminishes, necessitating the continuous development of novel compounds. This ongoing requirement for new pharmaceutical agents directly impedes market expansion by escalating development costs and increasing regulatory complexities.

Key Market Trends

The growing adoption of AI-driven drug discovery for antivirals represents a significant shift in pharmaceutical research, aiming to accelerate the identification and development of novel compounds. This trend leverages advanced computational techniques to analyze vast biological datasets, predict molecular properties, and optimize drug designs, thereby streamlining the notoriously lengthy and expensive drug development process. According to a survey from cloud vendor Rackspace Technology and Dell/VMware conducted in October 2023, 67% of pharmaceutical companies planned to increase their IT investments, including AI, over the subsequent 12 months, highlighting this strategic pivot.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • GSK plc.
  • AbbVie, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Aurobindo Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Anti-Viral Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Viral Drugs Market, By Type:

  • Branded
  • Generics

Anti-Viral Drugs Market, By Drug Class:

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

Anti-Viral Drugs Market, By Application:

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

Anti-Viral Drugs Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Anti-Viral Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Viral Drugs Market.

Available Customizations:

Global Anti-Viral Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Viral Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Branded, Generics)
    • 5.2.2. By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
    • 5.2.3. By Application (HIV, Hepatitis, Herpes, Influenza, Others)
    • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Anti-Viral Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anti-Viral Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Anti-Viral Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Anti-Viral Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Distribution Channel

7. Europe Anti-Viral Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anti-Viral Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Anti-Viral Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Anti-Viral Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Anti-Viral Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Anti-Viral Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Anti-Viral Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anti-Viral Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Anti-Viral Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Anti-Viral Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Anti-Viral Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Anti-Viral Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Anti-Viral Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anti-Viral Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Anti-Viral Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Anti-Viral Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Distribution Channel

10. South America Anti-Viral Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Viral Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Anti-Viral Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Anti-Viral Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anti-Viral Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GSK plc.
  • 15.3. AbbVie, Inc.
  • 15.4. Merck & Co., Inc.
  • 15.5. Johnson & Johnson Services, Inc.
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Aurobindo Pharma
  • 15.8. Cipla Limited
  • 15.9. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer